|
 Panagin
Pharmaceuticals Inc., a privately-held biotech company, specializes
in the discovery, research, development and commercialization
of saponin based anti-cancer drugs. Panagin's proprietary new
drug candidates show strong anti-cancer properties against various
advanced, metastatic, multi-drug resistant cancers.
Panagin's
research and clinical programs focus on life-threatening diseases,
such as lung cancer, pancreatic cancer, and brain metastases
from various original sites.
Panagin's
goal is to provide pharmaceutical treatment for cancers using
saponin technology. Its growth strategy is to develop one or
more of its portfolio candidates to Phase II clinical trials
for cancer indications that currently do not have effective
treatment.
Panagin
has completed pre-IND communications with US FDA. In 2004, the
Company is preparing to file IND and conduct Phase I clinical
studies of PBD-2131B (oral) for the treatment of lung cancer
and other solid tumours. In 2005, Panagin plans to advance another
drug candidate PAM-200 to the clinic for the treatment of brain
metastases from original lung cancer.
Pandimex™
(PBD-2131B injection), has received conditional market approval
in China for the treatment of advanced cancers of lung, breast,
pancreas, stomach and colon-rectum. Pandimex™ can be used
as a single agent and combination agent with paclitaxel. A Panagin-controlled
joint venture is formed to market Pandimex™, and to upgrade
its regulatory status to a full NDA approval.
Panagin's
key strengths include:
- Strong
scientific research programs and strong proof-of-concept data
- Strong
and focused clinical programs
- Market
success in China will potentially make the Company sustainable
- Extensive
patent portfolio
- Experienced
management and scientific advisory teams
Panagin's
laboratory and administrative offices are located in the suburb
of Vancouver, British Columbia, Canada. The Company works collaboratively
with the University of British Columbia, Vancouver General Hospital,
BC Cancer Agency, and Simon Fraser University. Panagin also
has world-renowned clinical trial leaders & scientific advisors
from the Arizona Cancer Center at The University of Arizona
in Tucson, BC Cancer Agency, the University of British Columbia
and Simon Fraser University. The Company seeks strategic partners
in the further development of its technology portfolio.
|
